Astex Pharmaceuticals , a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
NovaBiotics Ltd (NovaBiotics), a clinical-stage anti-infectives biotechnology company, announces receipt of Fast Track Designation (FTD) for its cystic fibrosis (CF) therapy, Lynovex®, from the United States Food and Drug Administration (FDA).
Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.
LifeArc®, the medical research charity, today announced its Philanthropic Fund will award £5M in grants to support medical research projects focused on rare diseases. The grants scheme was announced at the Drug Repurposing for Rare Diseases Conference 2018.
Prokarium today announced the completion of a $10 million investment round. The round was led by Riyadh Valley Company, followed by Prokarium’s original investor Flerie Invest as well as Korea Investment Partners.
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.
Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies, demonstrating Horizon’s ability to generate revenues from internally derived IP. Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic reference standards, and cell therapy
ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), today announced successful results from its Phase IIa placebo-controlled challenge trial in healthy adult subjects infected intranasally with respiratory syncytial virus (RSV).